Inflammatory Breast Carcinoma: Outcomes with Trimodality Therapy for Nonmetastatic Disease

Cancer

Volumn 100, Issue 5, 2004, Pages 920-928

  Liauw, Stanley L ^a   Benda, Rashmi K ^a   Morris, Christopher G ^a   Mendenhall, Nancy Price ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Department of Radiation Oncology ^*  (United States)

Author keywords

Breast neoplasms; Neoadjuvant therapy; Radiation therapy; Treatment outcome

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; TAMOXIFEN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE COURSE; FEMALE; HUMAN; INFLAMMATORY BREAST CANCER; MAJOR CLINICAL STUDY; MASTITIS; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SURVIVAL RATE; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROBABILITY; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SAMPLING STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1242314238     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20083     Document Type: Article

References (47)

1. Jaiyesimi LA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol. 1992;10:1014-1024.
2. Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 1975-1992. Cancer. 1998;82:2366-2372.
3. Anderson WF, Chu KC, Chang S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol. 2003;21:2254-2259.
4. Cristofanilli M, Buzdar AV, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist. 2003;8:141-418.
5. Fein DA, Mendenhall NP, Marsh RD, Bland KI, Copeland EM III, Million RR. Results of multimodality therapy for inflammatory breast cancer: an analysis of clinical and treatment factors affecting outcome. Am Surg. 1994;60:220-225.
6. Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging manual, 6th edition. New York: Springer-Verlag, 2002.
7. Hintze J. Number cruncher statistical system (NCSS) statistical software. Kaysville, UT: NCSS, 2000.
8. SAS Institute Inc. SAS OnlineDoc®, version 8. Cary, NC: SAS Institute Inc., 1999.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
10. DeBoer RH, Allum WH, Ebbs SR, et al. Multimodality therapy in inflammatory breast cancer: is there a place for surgery? Ann Oncol. 2000;11:1147-1153.
11. Koh EH, Buzdar AU, Ames FC, et al. Inflammatory carcinoma of the breast: results of a combined-modality approach - M.D. Anderson experience. Cancer Chemother Pharmacol. 1990;27:94-100.
12. Donegan WL, Padrta B. Combined therapy for inflammatory breast cancer. Arch Surg. 1990;125:578-582.
13. Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer. 1994;74:466-476.
14. Fleming RY, Asmar L, Buzdar AU, et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol. 1997;4:452-461.
15. Schafer P, Alberto P, Forni M, Obradovic D, Pipard G, Krauer F. Surgery as part of a combined modality approach for inflammatory breast carcinoma. Cancer. 1987;59:1063-1067.
16. Brun B, Otmezguine Y, Feuilhade F, et al. Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation. Cancer. 1988;61:1096-1103.
17. Pierce LJ, Lippman M, Ben-Baruch N, et al. The effect of systemic therapy on local-regional control in locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 1992;23:949-960.
18. Arriagada R, Mouriesse H, Spielmann M, et al. Alternating radiotherapy and chemotherapy in non-metastatic inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1990;19:1207-1210.
19. Chevallier B, Asselain B, Kunlin A, Veyret C, Bastit P, Graic Y. Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis. Cancer. 1987;60:897-902.
20. Palangie T, Mosseri V, Mihura J, et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer. 1994;30A:921-927.
21. Tubiana-Mathieu N, Lejeune C, Bonnier P, et al. Chemotherapy and concomitant irradiation in inflammatory breast cancer. Anticancer Res. 2001;21:3061-3067.
22. Thomas F, Arriagada R, Spielmann M, et al. Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. Cancer. 1995;76:2286-2290.
23. Rouesse J, Friedman S, Sarrazin D, et al. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol. 1986;4:1765-1771.
24. Chevallier B, Bastit P, Graic Y, et al. The Centre H. Becquerel studies in inflammatory non-metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer. 1993;67:594-601.
25. Mourali N, Tabbane F, Muenz LR, et al. Ten-year results utilizing chemotherapy as primary treatment in nonmetastatic, rapidly progressing breast cancer. Cancer Invest. 1993;11:363-370.
26. Peters GN, Kardinal CG, Robidoux A, Hortobagyi GN. Inflammatory breast cancer: what is the appropriate therapy for patients who have a clinical response to induction chemotherapy? Semin Oncol. 1995;22:xiv, xxi-xxvi, xxxii.
27. Wolff AC, Davidson NE. Primary systemic therapy in operable breast cancer. J Clin Oncol. 2000;18:1558-1569.
28. Bonnier P, Charpin C, Lejeune C, et al. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer. 1995;62:382-385.
29. Levine PH, Steinhorn SC, Ries LG, Aron JL. Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) Program. J Natl Cancer Inst. 1985;74:291-297.
30. Ellis DL, Teitelbaum SL. Inflammatory carcinoma of the breast. A pathologic definition. Cancer. 1974;33:1045-1047.
31. Saltzstein SL. Clinically occult inflammatory carcinoma of the breast. Cancer. 1974;34:382-388.
32. Lucas FZ, Perez-Mesa C. Inflammatory carcinoma of the breast. Cancer. 1978;41:1595-1605.
33. Amparo RS, Angel CD, Ana LH, et al. Inflammatory breast carcinoma: pathological or clinical entity? Breast Cancer Res Treat. 2000;64:269-273.
34. Kleer CG, van Golden KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res. 2000;2:423-429.
35. Barker JL, Nelson AJ, Montague ED. Inflammatory carcinoma of the breast. Radiology. 1976;121:173-176.
36. Liao Z, Strom EA, Buzdar AU, et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys. 2000;47:1191-1200.
37. Pisansky TM, Schaid DJ, Loprinzi CL, Donohue JH, Schray MF, Schomberg PJ. Inflammatory breast cancer: integration of irradiation, surgery, and chemotherapy. Am J Clin Oncol. 1992;15:376-387.
38. Maloisel F, Dufour P, Bergerat JP, et al. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer. 1990;65:851-855.
39. Harris EE, Schultz D, Bertsch H, Fox K, Glick J, Solin LJ. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003;55:1200-1208.
40. Adkins D, Brown R, Trinkaus K, et al. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in Stage IIIB inflammatory breast cancer. J Clin Oncol. 1999; 17:2006-2014.
41. Buzdar AU, Singletary SE, Booser DJ, et al. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Clin Oncol North Am. 1995;4:715-734.
42. Galmarini CM, Garbovesky C, Galmarini D, Galmarini FC. Clinical outcome and prognosis of patients with inflammatory breast cancer. Am J Clin Oncol. 2002;25:172-177.
43. Thoms WW, McNeese MD, Fletcher GH, Buzdar AU, Singletary SE, Oswald MJ. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1989;17:739-745.
44. Curcio LD, Rupp E, Williams WL, et al. Beyond palliative mastectomy in inflammatory breast cancer - a reassessment of margin status. Ann Surg Oncol. 1999;6:249-254.
45. Attia-Sobol I, Ferriere JP, Cure H, et al. Treatment results, survival and prognostic factors in 109 inflammatory breast cancer: univariate and multivariate analysis. Eur J Cancer. 1993;29A:1081-1088.
46. Brooks HL, Mandava N, Pizzi WF, Shah S. Inflammatory breast carcinoma: a community hospital experience. J Am Coll Surg. 1998;186:622-629.
47. Fields IN, Kuske RR, Perez CA, Fineberg BB, Bartlett N. Prognostic factors in inflammatory breast cancer. Univariate and multivariate analysis. Cancer. 1989;63:1225-1232.